Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Octostim
Incorrect volume was detected in some packs and out-of-specification results for the content of the active substance desmopressin and the excipient benzalkonium chloride. Potential effects: lack of treatment efficacy or adverse effects due to incorrect dosing.
Dicortineff
Occurrence of a quality defect in the medicinal product in the fludrocortisone acetate parameter, confirmed in stability testing and an archival sample. Potential effects: possible lack of treatment efficacy or unpredictable adverse reactions.
Ventolin
The quality defect consists in marking the batch with a unique identifier indicating in the system that the batch is withdrawn, which prevents dispensing the product to patients and may lead to lack of availability of the medicine. Potential effects: lack of effective treatment, deterioration of health.
Megalia
Out-of-specification results were found regarding microbiological purity in batches of the medicinal product Megalia. Potential effects: infection, complications, risk to patients' health.
Monural
Use of the product, for which the benefit-risk balance was judged negative, poses a threat to public health and may directly endanger patients’ health or life. Potential effects: serious adverse reactions, lack of treatment efficacy, complications threatening health or life.
Monural
Use of this product, for which the benefit–risk ratio has been considered negative, poses a threat to public health. Potential effects: serious adverse reactions, health risk, possible complications.
Uromaste
Use of the product, for which the benefit–risk balance was assessed as negative, poses a threat to public health; there is a significant probability of real harm to patients’ health or life. Potential effects: treatment complications, lack of efficacy, threat to health or life.
Uromaste
It was found that use of the product, for which the benefit–risk balance was judged negative, poses a threat to public health. Potential effects: serious adverse reactions or lack of effectiveness in infection treatment.
Furosemidum Polfarmex
The quality defect involves a mix-up of Furosemidum Polfarmex and Nasen packs, creating a risk that patients take the wrong medicine and consequently face a threat to their life or health. Potential effects: lack of efficacy, increased adverse effects, serious complications, life-threatening situations.
Nasen
A quality defect consisting in placing in the outer packaging of one medicinal product the blisters of another medicinal product, creating a risk that the patient will take the wrong medicine. Potential effects: inappropriate treatment, lack of therapeutic efficacy, serious adverse reactions.
Espumisan
Information leaflets for the medicinal product Zentel tablets were detected in some packs instead of the correct ESPUMISAN leaflet. Potential effects: improper use of the medicine, incorrect dosing, lack of efficacy or adverse reactions.
Groprinosin Max
Out-of-specification results were found in antimicrobial preservation efficacy tests for Groprinosin MAX, meaning lack of adequate preservation and a risk of infection after use. Potential effects: infections, complications, health risk for patients.
Sulfarinol
An out-of-specification result was obtained in stability testing for batch 020618 concerning the parameter “naphazoline nitrate contamination – other single impurity”, with the possibility that this quality defect may occur in other batches still on the market. Potential effects: nasal mucosa irritation, adverse reactions or reduced treatment effectiveness.
Cisatracurium Noridem
The tested sample of the medicinal product does not meet the requirements specified in the documentation for active substance content and product appearance, which creates a potential risk to patients' health or life. Potential effects: lack of treatment efficacy, complications during anaesthesia, life-threatening risk.
Megalia
Failure to meet quality requirements for the batch regarding microbiological purity, which poses a potential risk to patients’ health or life and was the basis for granting the decision immediate enforceability. Potential effects: infection, complications, lack of treatment safety.
Montelukast Bluefish
A discrepancy was found between the outer packaging and the Summary of Product Characteristics – a product intended for children aged 6–14 years was labelled as for children 2–5 years, which poses a threat to public health. Potential effects: improper use in children, risk of lack of efficacy or adverse effects.
Ebetrexat
It was found that the sample did not meet the product specification requirements for purity; the out-of-specification result concerned the parameter "content of related substance impurities". Potential effects: altered drug effect, possible increased adverse reactions or complications of therapy.
Clopidogrel Genoptim
The previously identified quality defect was the placement of an incorrect active substance name on the unit packaging of the medicinal product Clopidogrel Genoptim. Potential effects: incorrect use of the medicine, lack of treatment efficacy, possible treatment complications.
Gardimax Medica Spray
The advertisement of Gardimax Medica Spray and Dektac 25 mg film-coated tablets is misleading regarding their properties, suggesting they fight viruses and fever, although such indications are not included in the Summary of Product Characteristics or the patient leaflet. Potential effects: improper use of the medicine, lack of treatment efficacy, delay of appropriate therapy.
Dektac
It was found that the advertising of Gardimax Medica Spray and Dektac 25 mg film-coated tablets is misleading, attributing to them effects of “combating viruses” and “combating fever” that are not consistent with the approved Summary of Product Characteristics. Potential effects: incorrect use of the medicine, lack of treatment efficacy, possible complications.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.